Expression of terminal α2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13

Blood

Volumn 115, Issue 13, 2010, Pages 2666-2673

  McGrath, Rachel T ^a   McKinnon, Thomas A J ^b   Byrne, Barry ^c   O'Kennedy, Richard ^c   Terraube, Virginie ^a   McRae, Emily ^a   Preston, Roger J S ^a   Laffan, Mike A ^b   O'Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CHYMOTRYPSIN; CYSTEINE PROTEINASE; GLYCAN DERIVATIVE; SERINE PROTEINASE; SIALIC ACID DERIVATIVE; SIALIDASE; TRYPSIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ALPHA N ACETYLGALACTOSAMINIDASE; BIOPOLYMER; COLLAGEN; GALACTOSE; GLYCOPEPTIDASE; GLYCOSIDASE; N ACETYLNEURAMINIC ACID;

ARTICLE; BINDING AFFINITY; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIALYLATION; CHEMISTRY; COMPARATIVE STUDY; CONFORMATION; DRUG EFFECT; ENZYME SPECIFICITY; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN PROCESSING;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; ALPHA-N-ACETYLGALACTOSAMINIDASE; BIOPOLYMERS; CARBOHYDRATE CONFORMATION; COLLAGEN; CYSTEINE PROTEASES; GALACTOSE; GLYCOSIDE HYDROLASES; HUMANS; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; PEPTIDE-N4-(N-ACETYL-BETA-GLUCOSAMINYL) ASPARAGINE AMIDASE; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SERINE PROTEASES; SUBSTRATE SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 77951017195     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-241547     Document Type: Article

References (50)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
2. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1(7):1335-1342.
3. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191. (Pubitemid 40299779)
4. Wormald MR, Dwek RA. Glycoproteins: glycan presentation and protein-fold stability. Structure. 1999;7(7):R155-R160.
5. Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A. 1995;92(7):2455-2459.
6. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost. 1998;79(6):1068-1079.
7. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986;102(4):1320-1324. (Pubitemid 16038076)
8. de Wit TR, van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: biological implications. Best Pract Res Clin Haematol. 2001;14(2):241-255.
9. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977. (Pubitemid 35332036)
10. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435.
11. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106(11):11-17.
12. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25(11):3171-3184. (Pubitemid 16056960)
13. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984;99(6):2123-2130.
14. Debeire P, Montreuil J, Samor B, et al. Structure determination of the major asparagine-linked sugar chain of human factor VIII-von Willebrand factor. FEBS Lett. 1983;151(1):22-26. (Pubitemid 13139207)
15. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem. 1992;267(13):8723-8731.
16. Samor B, Mazurier C, Goudemand M, Debeire P, Fournet B, Montreuil J. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf). Thromb Res. 1982;25(1-2):81-89. (Pubitemid 12185143)
17. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J. 1989;6(3):263-270. (Pubitemid 19232054)
18. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003;1(1):33-40.
19. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111(6):3042-3049.
20. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106(6):1988-1991.
21. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11(4):343-351. (Pubitemid 32771926)
22. Byrne B, Donohoe GG, O'Kennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today. 2007;12(7-8):319-326. (Pubitemid 46467485)
23. Federici AB, Elder JH, De ML, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest. 1984;74(6):2049-2055.
24. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335-341. (Pubitemid 34127049)
25. Anumula KR. Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. Anal Biochem. 1995;230(1):24-30.
26. Larkin D, de LB, Jenkins PV, et al. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog. 2009;5(3):e1000349.
27. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A. 2008;105(21):7416-7421. (Pubitemid 351830032)
28. Gralnick HR, Williams SB, Rick ME. Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein. Proc Natl Acad Sci U S A. 1983;80(9):2771-2774.
29. Kimura N, Uchida M, Nishimura S, Yamaguchi H. Promotion of polypeptide folding by interactions with Asn-Glycans. J Biochem. 1998;124(4):857-862. (Pubitemid 28488168)
30. Mitra N, Sinha S, Ramya TN, Surolia A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci. 2006;31(3):156-163. (Pubitemid 43357996)
31. Narhi LO, Arakawa T, Aoki KH, et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem. 1991;266(34):23022- 23026. (Pubitemid 21908754)
32. Wyss DF, Choi JS, Li J, et al. Conformation and function of the N-linked glycan in the adhesion domain of human CD2. Science. 1995;269(5228):1273-1278.
33. Gralnick HR. Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity. J Clin Invest. 1978;62(2):496-499.
34. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A. 2002;99(15):10042-10047. (Pubitemid 34831169)
35. Cohen M, Hurtado-Ziola N, Varki A. ABO blood group glycans modulate sialic acid recognition on erythrocytes. Blood. 2009;114(17):3668-3676.
36. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
37. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109(5):1998-2000. (Pubitemid 46348198)
38. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583-588. (Pubitemid 351418945)
39. Nishiyama T, Kimura N, Jitsuhara Y, Uchida M, Ochi F, Yamaguchi H. N-Glycans protect proteins from protease digestion through their binding affinities for aromatic amino acid residues. J Biochem. 2000;127(3):427-433. (Pubitemid 30185247)
40. Toyoda T, Arakawa T, Yamaguchi H. N-glycans stabilize human erythropoietin through hydrophobic interactions with the hydrophobic protein surface: studies by surface plasmon resonance analysis. J Biochem. 2002;131(4):511-515. (Pubitemid 34456605)
41. Jitsuhara Y, Toyoda T, Itai T, Yamaguchi H. Chaperone-like functions of high-mannose type and complex-type N-glycans and their molecular basis. J Biochem. 2002;132(5):803-811. (Pubitemid 35408505)
42. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR. Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology. 2004;14(2):103-114.
43. Federici AB, De Romeuf C, de Groot PG, et al. Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF). Blood. 1988;71(4):947-952.
44. Bulai T, Bratosin D, Pons A, Montreuil J, Zanetta JP. Diversity of the human erythrocyte membrane sialic acids in relation with blood groups. FEBS Lett. 2003;534(1-3):185-189. (Pubitemid 36084540)
45. Udoh AE. Distribution of sialic acid between sialoglycoproteins and other membrane components of different erythrocyte phenotypes. Acta Physiol Hung. 1991;78(3):265-273.
46. Lopes AA, Ferraz de Souza B, Maeda NY. Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension. Thromb Haemost. 2000;83(5):683-687.
47. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977;252(15):5538-5546.
48. Gralnick HR, Coller BS, Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor protein in von Willebrand's disease variants. Science. 1976;192(4234):56-59.
49. van Schooten CJ, Denis CV, Lisman T, et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood. 2007;109(6):2430-2437. (Pubitemid 46425885)
50. Eikenboom J, Van M, V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4(4):774-782.